Source: Health Products Regulatory Authority (IE) Revision Year: 2019 Publisher: Teofarma S.R.L, Valle Salimbene (PV), Via F. LLI Cervi, 8 CAP 27010, Italy
Ferrograd 325mg Prolonged release Tablets.
| Pharmaceutical Form |
|---|
|
Prolonged release tablet. Circular, biconvex, red film-coated tablet. |
Each tablet contains Dried Ferrous Sulphate 325mg (elemental iron 105mg).
Excipients with known effect: Each tablet contains 19.4mg lactose monohydrate and sunset yellow FCF (E110).
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Ferrous sulfate |
Iron sulphate is a co-factor of various enzymes necessary for the transfer of energy (eg. cytochrome oxidase, xanthine oxidase). Iron is also present in hemoglobin and myoglobin, which are essential for the transport and use of oxygen. |
| List of Excipients |
|---|
|
Core: Methylacrylate methylmethacrylate copolymer Film coating: Hypromellose |
Carton containing 30 (3 × 10) tablets in an AL/PVC blister.
Teofarma S.R.L, Valle Salimbene (PV), Via F. LLI Cervi, 8 CAP 27010, Italy
PA1235/001/001
Date of first authorisation: 01 April 1980
Date of last renewal: 01 April 2010
| Drug | Countries | |
|---|---|---|
| FERROGRAD | Ireland, Malta, New Zealand, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
